Abstract:Objective: To evaluate and compare the efficacy and safety of ultra-rapid lispro insulin (URLi) and humalog lispro (HL) in the treatment of type 2 diabetes mellitus. Methods: This was an international multicenter, double-blind, randomized controlled study. From May 2019 to January 2021, a total of 481 patients with type 2 diabetes mellitus, who had been using insulin for at least 90 days and had poor glycemic control, were included. These patients were recruited from 34 research centers in China, including Shanghai Jiao Tong University School of Medicine Affiliated Sixth People's Hospital. They were assigned to either the URLi group (319 patients) or the HL group (162 patients) using stratified blocked randomization. The primary endpoint was the change in hemoglobin A1c (HbA1c) relative to baseline after 26 weeks of treatment. Secondary endpoints included the proportion of patients who achieved HbA1c<7.0% and ≤6.5% after 26 weeks of treatment, 1-h postprandial glucose (1hPG) or 2-h postprandial glucose (2hPG) excursions during a mixed meal tolerance test at week 26, as well as safety parameters. Continuous variables were compared using mixed model repeated measures or analysis of covariance, and categorical variables were compared using logistic regression or Fisher's exact test. Results: Data based on the Chinese subgroup showed that there were no statistically significant differences between the URLi and HL groups in terms of male percentage [56.1% (179/319) vs. 56.2% (91/162); P=0.990], age [(59.5±8.4) vs. (59.6±9.3) years; P=0.839] and other baseline characteristics. Regarding the change in HbA1c relative to baseline, the URLi group was non-inferior to the HL group (-0.59%±0.05% vs. -0.66%±0.06%; P=0.312). There were no statistically significant differences between the URLi and HL groups in proportion of patients who achieved HbA1c<7.0% [47.3% (138/292) vs. 45.2% (70/155); P=0.907] and≤6.5% [27.7% (81/292) vs. 27.7% (43/155); P=0.816]. The excursions in 1hPG [(6.20±0.21) vs. (6.90±0.25) mmol/L; P=0.001] and 2hPG [(8.10±0.27) vs. (9.30±0.31) mmol/L; P<0.001] were lower in the URLi group than the HL group, with statistically significant differences. In terms of safety, there were no statistically significant differences in the percentage of subjects who reported treatment-emergent adverse events between the URLi and HL groups [49.8% (159/319) vs. 50.0% (81/162); P=1.000]. The event rate of nocturnal hypoglycemia was lower in the URLi group than the HL group, with statistically significant differences [(0.53±0.10) vs. (0.89±0.16) events per patient-year; P=0.040]. Conclusions: With good glycemic control, URLi showed non-inferiority for HbA1c improvement versus HL and was superior to HL for postprandial glucose excursion control. Meanwhile the rate and incidence of nocturnal hypoglycemia were lower in the URLi group than the HL group.

Comparison of insulin lispro mix 25 with insulin lispro mix 50 as an insulin starter in Asian patients with type 2 diabetes: a phase 4, open-label, randomized trial (CLASSIFY study).

Comparison of Insulin Lispro Mix 25 with Insulin Lispro Mix 50 As Insulin Starter in Chinese Patients with Type 2 Diabetes Mellitus (CLASSIFY Study): Subgroup Analysis of a Phase 4 Open-Label Randomized Trial.

Comparison of Insulin Intensification Strategies with Insulin Lispro Low Mixture Twice Daily Versus Basal Insulin Glargine and Prandial Insulin Lispro Once Daily in East Asian and Caucasian Patients with Type 2 Diabetes Mellitus.

Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study.

Pharmacokinetics and Pharmacodynamics of 40/60 Premixed Recombinant Human Insulin Injection Preparations

A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: Results of the PARADIGM study

[Efficacy and safety of ultra rapid lispro in the treatment of type 2 diabetes mellitus: a randomized controlled clinical trial]

Comparison of the efficacy and safety of two kinds of mixed protamine Zinc recombinant human insulin lispro injection (50R) in the treatment of diabetes: a multicenter, randomized, parallel, positive controlled clinical trial

Comparison of the Efficacy and Safety of Insulin Glulisine and Insulin Lispro Combined with Insulin Glargine in Patients with Diabetes

Bioequivalence Between Two Human Insulin Analogs in Chinese Population: Glulisine and Lispro

Comparable Efficacy and Safety Between LY2963016 Insulin Glargine and Insulin Glargine (lantus®) in Chinese Patients with Type 1 Diabetes: A Phase III, Randomized, Controlled Trial.

Comparison of efficacy and safety between biphasic insulin aspart 50 and biphasic human insulin 50：A randomized crossover trial

Ultra-rapid Lispro Improved Postprandial Glucose Control Compared to Insulin Lispro in Predominantly Chinese Patients with Type 1 Diabetes: A Prospective, Randomized, Double-Blind Phase 3 Study.

Potential Value of the Asian Treat to Target Lantus Study（ ATLAS） for Type 2 Diabetes Management in China:safety and Efficacy of Two Treatment Algorithms Using Insulin Glargine

Efficacy of Once-Daily Glucagon-Like Peptide-1 Receptor Agonist Lixisenatide As an Add-on Treatment to Basal Insulin in Asian and White Adults with Type 2 Diabetes Mellitus: an Individual-Level Pooled Analysis of Phase III Studies

Comparison of the Effect Between Insulin Lispro 75/25 and Humulin 70/30 on the Postprandial Blood Glucose Excursion in Patients with Diabetes

Effects of Premixed Insulin Lispro versus Insulin Glargine on Type 2 Diabetes Mellitus: A Meta-Analysis

A Pragmatic Study of Mid‐mixture Insulin and Basal Insulin Treatment in Patients with Type 2 Diabetes Uncontrolled with Oral Antihyperglycaemic Medications: A Lesson from Real‐world Experience

PDB59 LIXISENATIDE, BASAL INSULIN AND PREMIXED INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY ORAL ANTIDIABETIC DRUGS: NETWORK META-ANALYSIS AND COST-EFFECTIVENESS ANALYSIS

Ultra rapid lispro improves postprandial glucose control versus lispro in combination with basal insulin: a study based on CGM in type 2 diabetes in China